Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Daniel Petrylak shares interim results from Duravelo-2, a study of zelenectide in patients with one prior line of therapy for metastatic urothelial carcinoma. Zelenectide is a bicyclic peptide ...
Yijun Shen discusses phase two results from a single-arm study of SHR-A2102 plus adebrelimab as neoadjuvant therapy in muscle-invasive bladder cancer. SHR-A2102 is a nectin-4 antibody-drug conjugate ...
Jeffrey Zhong discusses a retrospective UNITE consortium analysis of dose modifications of enfortumab vedotin plus pembrolizumab in 360 patients with advanced urothelial carcinoma ...
Susan Halabi presents a ctDNA-based prognostic model for radiographic progression-free survival in mCRPC patients receiving first-line androgen receptor pathway inhibitors. The mo ...
(UroToday.com) The 2026 ASCO annual meeting featured a bladder cancer session and a presentation by Dr. Earle Burgess discussing clinical outcomes with ERBB2 gene amplification and activating ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a prostate, testicular, and penile cancers rapid oral abstracts session. Dr. Fred Saad presented the ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Robert Motzer presented the final analysis of the ...
AUA 2026, BCG naive and BCG-Exposed High-Risk Non–muscle Invasive Bladder Cancer, Intravesical MK-3120, anti–Nectin-4 monoclonal antibody, MK-3120 I-VESIC.
(UroToday.com) The 2026 Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a management and prevention of frequent side effects and modifying the metabolism session, and a ...
(UroToday.com) The 2026 GU ASCO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Roger Li discussing the phase 2 INTerpath-011 study assessing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results